Marco C. Miotto
Rosario, S S2002LRK, Argentina
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Aroylhydrazones constitute a promising class of 'metal-protein attenuating compounds' for the treatment of Alzheimer's disease: a proof-of-concept based on the study of the interactions between zinc(II) and pyridine-2-carboxaldehyde isonicotinoyl hydrazone.
Journal: Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry
Published: June 18, 2018
Bioinorganic Chemistry of Parkinson's Disease: Affinity and Structural Features of Cu(I) Binding to the Full-Length β-Synuclein Protein.
Journal: Inorganic chemistry
Published: August 19, 2017
Copper Coordination Features of Human Islet Amyloid Polypeptide: The Type 2 Diabetes Peptide.
Journal: Inorganic chemistry
Published: October 06, 2016
A moderate metal-binding hydrazone meets the criteria for a bioinorganic approach towards Parkinson's disease: Therapeutic potential, blood-brain barrier crossing evaluation and preliminary toxicological studies.
Journal: Journal of inorganic biochemistry
Published: October 02, 2016
Disruption of zinc and copper interactions with Aβ(1-40) by a non-toxic, isoniazid-derived, hydrazone: a novel biometal homeostasis restoring agent in Alzheimer's disease therapy?
Journal: Metallomics : integrated biometal science
Published: April 11, 2015
Bioinorganic chemistry of synucleinopathies: deciphering the binding features of Met motifs and His-50 in AS-Cu(I) interactions.
Journal: Journal of inorganic biochemistry
Published: July 09, 2014
Site-specific copper-catalyzed oxidation of α-synuclein: tightening the link between metal binding and protein oxidative damage in Parkinson's disease.
Journal: Inorganic chemistry
Published: April 15, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026